In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
With Novartis’s oral contender looming, Astra talks up the importance of terminal complement inhibition.
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
Pfizer keeps declining, but it is not the only pandemic player to suffer.
Hopes for a better 2023 look optimistic as markets take another turn for the worse.